GT201400090A - 2-tiopirimidinonas - Google Patents

2-tiopirimidinonas

Info

Publication number
GT201400090A
GT201400090A GT201400090A GT201400090A GT201400090A GT 201400090 A GT201400090 A GT 201400090A GT 201400090 A GT201400090 A GT 201400090A GT 201400090 A GT201400090 A GT 201400090A GT 201400090 A GT201400090 A GT 201400090A
Authority
GT
Guatemala
Prior art keywords
inhibitors
thiopirimidinones
conversa
converse
treat
Prior art date
Application number
GT201400090A
Other languages
English (en)
Inventor
Carpino Philip Albert
Conn Edward Lee
Hepworth David
Kung Daniel Wei-Shung
Rocke Benjamin Neil
Ruggeri Roger Benjamin
Warmus Joseph Scott
Zhang Yan
Dow Robert Lee
Dowling Matthew Scott
Orr Suvi Tuula Marjukka
Sammons Matthew Forrest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400090(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400090A publication Critical patent/GT201400090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

INHIBIDORES DE MIELOPEROXIDASA, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS INHIBIDORES Y EL USO DE LOS INHIBIDORES PARA TRATAR, POR EJEMPLO, AFECCIONES CARDIOVASCULARES Y ENFERMEDADES RELACIONADAS COMO INHIBIDORES DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE HMG-COA REDUCTASA.
GT201400090A 2011-11-11 2014-05-09 2-tiopirimidinonas GT201400090A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558605P 2011-11-11 2011-11-11

Publications (1)

Publication Number Publication Date
GT201400090A true GT201400090A (es) 2015-09-04

Family

ID=47356235

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400090A GT201400090A (es) 2011-11-11 2014-05-09 2-tiopirimidinonas

Country Status (34)

Country Link
US (4) US8835449B2 (es)
EP (1) EP2776405A1 (es)
JP (1) JP5731718B2 (es)
KR (1) KR101650262B1 (es)
CN (1) CN103917529B (es)
AP (1) AP2014007621A0 (es)
AR (1) AR088805A1 (es)
AU (1) AU2012335220B2 (es)
BR (1) BR112014011254A2 (es)
CA (1) CA2853024C (es)
CL (1) CL2014000996A1 (es)
CO (1) CO6960543A2 (es)
CR (1) CR20140179A (es)
CU (1) CU20140049A7 (es)
DO (1) DOP2014000098A (es)
EA (1) EA027324B1 (es)
EC (1) ECSP14004595A (es)
GE (1) GEP201706656B (es)
GT (1) GT201400090A (es)
HK (1) HK1196603A1 (es)
IL (2) IL232425A (es)
MA (1) MA35638B1 (es)
MD (1) MD20140044A2 (es)
MX (1) MX351299B (es)
NI (1) NI201400042A (es)
PE (1) PE20161219A1 (es)
PH (1) PH12014501032A1 (es)
SG (1) SG11201401531RA (es)
TN (1) TN2014000195A1 (es)
TW (2) TWI526433B (es)
UA (1) UA108713C2 (es)
UY (1) UY34442A (es)
WO (1) WO2013068875A1 (es)
ZA (1) ZA201403589B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
CA2853024C (en) * 2011-11-11 2017-08-22 Pfizer Inc. 2-thiopyrimidinones
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
KR20200083551A (ko) 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 아미노-티아졸 치환된 인돌-2-카르복스아미드
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2024038131A1 (en) 2022-08-18 2024-02-22 Astrazeneca Ab Inhibitors of myeloperoxidase

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088751A (en) 1972-04-07 1978-05-09 Colgate-Palmolive Company Self-heating cosmetic
US4171429A (en) 1977-03-29 1979-10-16 Research Corporation Pyrimidine to pyrimidine transformation process
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
JPS5770693A (en) 1980-10-22 1982-05-01 Fuji Photo Film Co Ltd Desensitizing composition
EP0422011A1 (de) 1988-05-05 1991-04-17 BASF Aktiengesellschaft Mittel auf der basis von uracil-derivaten zur wachstumsförderung und fettreduktion bei tieren
KR0155168B1 (ko) 1989-09-29 1998-11-16 미우라 아끼라 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
JPH0699170B2 (ja) 1990-01-19 1994-12-07 日東紡績株式会社 耐火被覆材
JPH0525144A (ja) 1991-04-15 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH0543555A (ja) 1991-08-13 1993-02-23 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
TW284688B (es) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
JPH063761A (ja) 1992-06-19 1994-01-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
KR0151811B1 (ko) 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법
JP3781200B2 (ja) 1994-04-27 2006-05-31 コニカミノルタホールディングス株式会社 ハロゲン化銀写真感光材料の処理方法
JP3261641B2 (ja) 1994-04-28 2002-03-04 コニカ株式会社 ハロゲン化銀写真感光材料の処理方法
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CZ151297A3 (cs) 1994-11-16 1998-07-15 Synaptic Pharmaceutical Corporation Dihydropyrimidinové sloučeniny a farmaceutické prostředky na jejich bázi
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US5719190A (en) 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
CA2253862A1 (en) 1996-05-16 1997-11-20 Wai C. Wong Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
NZ335992A (en) 1996-12-05 2001-09-28 Amgen Inc Substituted pyrimidinone and pyridone compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
EP0958296B1 (en) 1996-12-31 2003-07-30 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19731784A1 (de) 1997-07-24 1999-02-04 Bayer Ag Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide
US6130340A (en) 1998-01-13 2000-10-10 President And Fellows Of Harvard College Asymmetric cycloaddition reactions
US6211370B1 (en) 1998-01-13 2001-04-03 Harvard University Asymmetric cycloaddition reactions
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
EP2002837A1 (en) 1998-07-06 2008-12-17 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CA2252144A1 (en) 1998-10-16 2000-04-16 University Of Alberta Dual action anticancer prodrugs
DE19918725A1 (de) 1999-04-24 2000-10-26 Bayer Ag Substituierte N-Cyano-sulfonsäureanilide
IL146210A0 (en) * 1999-05-01 2002-07-25 Smithkline Beecham Plc Pyrimidinone compounds
CA2374902C (en) 1999-06-02 2009-09-15 Janssen Pharmaceutica N.V. Aminoalkyl substituted benzopyran derivatives for treating impaired fundic relaxation
IT1307786B1 (it) * 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
JP2001131133A (ja) 1999-08-23 2001-05-15 Sankyo Co Ltd 新規ミエロペルオキシダーゼ阻害物質およびその製造方法
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
GB0013655D0 (en) 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
JO2352B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Compounds for the treatment of non-adaptation of the bottom of the uterus
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
ATE261470T1 (de) 2000-07-14 2004-03-15 Akzo Nobel Nv Stabilisatorensystem, das hydroxysäuren enthält
DE10034803A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Sulfonsäureanilide
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
US6562966B2 (en) 2000-07-31 2003-05-13 Brandeis University Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids
WO2003011799A1 (en) 2000-07-31 2003-02-13 Brandeis University Kinetic resolutions of chirat 3- and 3-substituted carboxylic acids
US6562967B2 (en) 2000-07-31 2003-05-13 Brandeis University Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids
WO2002033128A2 (en) 2000-10-18 2002-04-25 Pharmasset Limited Multiplex quantification of nucleic acids in diseased cells
CN101862345B (zh) 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
DE10108995A1 (de) 2001-02-23 2002-09-05 Abbott Gmbh & Co Kg Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP1387893B1 (en) 2001-05-08 2006-11-29 AstraZeneca AB An assay for detecting inhibitors of the enzyme myeloperokidase
EP3042894A1 (en) 2001-08-10 2016-07-13 Shionogi & Co., Ltd. Antiviral agent
WO2003029224A1 (en) 2001-10-03 2003-04-10 Pharmacia Corporation 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
BR0213129A (pt) 2001-10-03 2004-08-10 Pharmacia Corp Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
WO2003057677A1 (en) 2002-01-11 2003-07-17 Syddansk Universitet Anti-retroviral 5,6-disubstituted acyclopyrimidine nucleoside derivatives
PL372887A1 (en) 2002-02-27 2005-08-08 Pfizer Products Inc. Acc inhibitors
AU2003216585A1 (en) 2002-04-10 2003-10-20 Orchid Chemicals And Pharmaceuticals Limited Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MXPA04011325A (es) 2002-05-16 2005-02-14 Bayer Cropscience Gmbh Derivados de piridina-carboxamida y su uso como plaguicidas.
EP1394242A3 (en) 2002-08-07 2004-04-21 Rohm And Haas Company Cyclic thioureas and their use as additives for lubricating oils
EP1394241A1 (en) 2002-08-07 2004-03-03 Rohm And Haas Company Cyclic thioureas as additives for lubricating oils
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20050096319A1 (en) 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
EP1603546A1 (en) 2003-02-21 2005-12-14 Tripep AB Glycinamide derivative for inhibiting hiv replication
CA2521606A1 (en) 2003-04-07 2004-10-21 Cortical Pty Ltd. Novel methods for the treatment of inflammatory diseases
SE0301232D0 (sv) * 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
US7485604B2 (en) 2003-05-27 2009-02-03 Fujifilm Corporation Lubricant composition and method for using and preparing thereof
US7947817B2 (en) 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
WO2005063751A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. 4’-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
CN102127053A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
GEP20084421B (en) 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
US7928207B2 (en) 2004-06-28 2011-04-19 Roche Molecular Systems, Inc Synthesis and compositions of nucleic acids comprising 2′-terminator nucleotides
US7745125B2 (en) 2004-06-28 2010-06-29 Roche Molecular Systems, Inc. 2′-terminator related pyrophosphorolysis activated polymerization
EP1616874A1 (en) 2004-07-14 2006-01-18 Universiteit Gent Mono- and bicyclic compounds with therapeutic activity and pharmaceutical compositions including them
WO2006022899A2 (en) 2004-08-12 2006-03-02 King Industries, Inc. Organometallic compositions and coating compositions
US7485729B2 (en) 2004-08-12 2009-02-03 King Industries, Inc. Organometallic compositions and coating compositions
WO2006031806A2 (en) 2004-09-10 2006-03-23 Atherogenics, Inc. 2-thiopyrimidinones as therapeutic agents
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006070292A2 (en) 2004-10-12 2006-07-06 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
SE0402591D0 (sv) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1731911A1 (fr) 2005-06-07 2006-12-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procédé utile pour la détection d'encéphalopathies
US7399786B2 (en) 2005-06-30 2008-07-15 Bexel Pharmaceuticals, Inc. Derivatives of amino acids for treatment of obesity and related disorders
EP1919930B1 (en) 2005-07-01 2016-09-14 Dako Denmark A/S New nucleic acid base pairs
EP1920073A2 (en) 2005-07-01 2008-05-14 Dako Denmark A/S Method of simultaneously visualizing multiple biological targets
MX2008002073A (es) 2005-08-12 2008-04-16 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios.
EP1963329B1 (en) 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
CA2635777A1 (en) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Combination therapy for diabetes
DE102006000649A1 (de) 2006-01-03 2007-07-05 Degussa Gmbh Universell einsetzbare Zusammensetzungen
DE102006000651A1 (de) 2006-01-03 2007-07-12 Degussa Gmbh Präparation aus Ionischen Flüssigkeiten und Harzen
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
JP5025144B2 (ja) 2006-02-28 2012-09-12 Ｊｘ日鉱日石エネルギー株式会社 内燃機関用潤滑油組成物
UY30267A1 (es) 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
TW200808649A (en) 2006-05-31 2008-02-16 Du Pont Process for purifying perfluorinated products
CN101460501A (zh) * 2006-06-05 2009-06-17 阿斯利康(瑞典)有限公司 作为髓过氧化物酶抑制剂的吡咯并[3，2-d]嘧啶-4-酮衍生物
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
SI2048145T1 (sl) 2006-08-04 2011-04-29 Toyama Chemical Co Ltd Spodbujevalec aktivnosti proteinske kinaze c, vsebujoäś derivat alkilnega etra ali sol le-tega
WO2008023249A1 (en) 2006-08-24 2008-02-28 Chemfit Speciality Chemicals (Pty) Ltd Polyvinylchloride composition
JP2010510245A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
WO2008065508A1 (en) 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
US20080153697A1 (en) 2006-12-22 2008-06-26 E. I. Dupont De Nemours And Company Mixtures of ammonia and ionic liquids
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
EA200971115A1 (ru) 2007-06-29 2010-04-30 Корея Рисерч Инститьют Оф Кемикал Текнолоджи Новые ингибиторы обратной транскриптазы вич
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP5043555B2 (ja) 2007-08-08 2012-10-10 株式会社カネカ 硬化性組成物
US20090054468A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090053176A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Combination 937
CN101918389A (zh) 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
JP2009167179A (ja) 2007-12-21 2009-07-30 Daiichi Sankyo Co Ltd 環状アミン化合物を含有する医薬
AU2009225984A1 (en) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
WO2009120872A2 (en) 2008-03-26 2009-10-01 Ada Technologies, Inc. High performance batteries with carbon nanomaterials and ionic liquids
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
GB2472554B (en) 2008-05-05 2012-12-05 Ada Technologies Inc High performance carbon nanocomposites for ultracapacitors
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
PT2334687E (pt) 2008-08-28 2012-04-13 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
GB0818063D0 (en) * 2008-10-02 2008-11-05 Univ Dundee Compounds
JP5206367B2 (ja) 2008-11-27 2013-06-12 コニカミノルタエムジー株式会社 ウレア化合物を含む有機圧電材料
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
CN102388038B (zh) 2009-03-11 2014-04-23 辉瑞大药厂 用作葡糖激酶活化剂的苯并呋喃基衍生物
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
WO2010124201A2 (en) 2009-04-23 2010-10-28 Invasc Therapeutics, Inc. Compositions and methods for treatment of cardiovascular disease
WO2010124237A1 (en) 2009-04-24 2010-10-28 Novabay Pharmaceuticals Inc. Methods of treating infections of the nail
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
EP2427450A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
WO2010136546A1 (en) 2009-05-27 2010-12-02 Université Libre de Bruxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
WO2010138901A1 (en) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
MX2011013034A (es) 2009-06-05 2012-02-08 Pfizer 1-(piperidin-4-yl)-pirazol derivados como moduladores de gpr 119.
CA2766033C (en) 2009-06-25 2016-09-20 Alkermes, Inc. Prodrugs of nh-acidic compounds
RS56352B2 (sr) 2009-06-25 2023-02-28 Alkermes Pharma Ireland Ltd Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
WO2011003018A2 (en) 2009-07-01 2011-01-06 Cornell University Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
DE102009037300A1 (de) 2009-08-14 2011-02-17 Merck Patent Gmbh Tetracyanoborate als Schmierstoffe
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2011057220A2 (en) 2009-11-09 2011-05-12 Northwestern University Compositions and methods for treating lymphoma
FR2953145B1 (fr) 2009-11-30 2013-07-19 Inst Francais Du Petrole Solution absorbante contenant un inhibiteur de degradation derive de la pyrimidine ou de la triazine et procede d'absorption de composes acides contenus dans un effluent gazeux
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
ES2352926B1 (es) 2010-12-07 2012-01-12 Universidad De Granada Fenucil deuterado y derivados, procedimiento para su preparación y usos de los mismos.
CA2853024C (en) * 2011-11-11 2017-08-22 Pfizer Inc. 2-thiopyrimidinones
JP6003761B2 (ja) 2013-03-27 2016-10-05 富士ゼロックス株式会社 送風管、送風装置及び画像形成装置
BR112017022340A2 (pt) * 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas

Also Published As

Publication number Publication date
HK1196603A1 (zh) 2014-12-19
WO2013068875A1 (en) 2013-05-16
TWI480269B (zh) 2015-04-11
EP2776405A1 (en) 2014-09-17
US9873673B2 (en) 2018-01-23
CR20140179A (es) 2014-06-12
US20130123230A1 (en) 2013-05-16
NI201400042A (es) 2014-10-01
US9399626B2 (en) 2016-07-26
TN2014000195A1 (fr) 2015-09-30
GEP201706656B (en) 2017-04-25
IL249039B (en) 2018-07-31
PE20161219A1 (es) 2016-11-17
TW201518281A (zh) 2015-05-16
IL249039A0 (en) 2017-01-31
US8841314B2 (en) 2014-09-23
ECSP14004595A (es) 2015-11-30
AU2012335220B2 (en) 2017-06-01
TW201332979A (zh) 2013-08-16
CN103917529B (zh) 2016-08-17
ZA201403589B (en) 2015-06-24
AU2012335220A1 (en) 2014-05-01
KR20140089603A (ko) 2014-07-15
CA2853024C (en) 2017-08-22
MX2014005721A (es) 2014-05-28
JP5731718B2 (ja) 2015-06-10
AR088805A1 (es) 2014-07-10
IL232425A0 (en) 2014-06-30
BR112014011254A2 (pt) 2017-05-16
CO6960543A2 (es) 2014-05-30
IL232425A (en) 2016-11-30
US20140288049A1 (en) 2014-09-25
CU20140049A7 (es) 2014-08-28
AP2014007621A0 (en) 2014-05-31
MD20140044A2 (ro) 2014-08-31
UY34442A (es) 2013-06-28
CN103917529A (zh) 2014-07-09
TWI526433B (zh) 2016-03-21
EA027324B1 (ru) 2017-07-31
PH12014501032A1 (en) 2014-10-20
US20130296351A1 (en) 2013-11-07
CL2014000996A1 (es) 2014-07-04
EA201490688A1 (ru) 2014-10-30
US8835449B2 (en) 2014-09-16
DOP2014000098A (es) 2014-07-31
MX351299B (es) 2017-10-10
SG11201401531RA (en) 2014-07-30
NZ624453A (en) 2015-12-24
MA35638B1 (fr) 2014-11-01
KR101650262B1 (ko) 2016-08-22
JP2014533261A (ja) 2014-12-11
UA108713C2 (xx) 2015-05-25
CA2853024A1 (en) 2013-05-16
US20160304469A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
GT201400090A (es) 2-tiopirimidinonas
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
CR20150370A (es) Compuestos antivirales
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CO7160104A2 (es) Inhibidores de virus de hepatitis c
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2015000944A1 (es) Compuestos de benceno sustituido
UY33735A (es) Compuestos antivirales
CO6761389A2 (es) Inhibidores de nampt y rock
CR20140405A (es) Apoptosis señal reguladores del inhibidor de quinasa
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
UY35210A (es) Inhibidores de autotaxina
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY35467A (es) Compuestos orgánicos
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
CL2015000956A1 (es) Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros.
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
CL2015002060A1 (es) Compuestos.
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.